Antituberculosis drug-induced hepatotoxicity is quite common. However, factors predicting its development are still controversial. The objective of the present study was to evaluate the role of certain factors (age and sex ofthe patient, alcoholism, chronic liver disease, hepatitis B virus carrier status, acetylator status, nutritional status and antituberculosis treatment (ATT) regimen) in predicting the development ofATT-induced hepatitis. In a case-control study, 60 consecutive patients with evidence of ATT-induced hepatitis were studied to assess the possible association of the above-mentioned factors with ATT-induced hepatitis. Body mass index was found to be significantly lower in ATT-induced hepatitis patients (17.2 ± 2.7) than in controls (19.5 ± 3.3) (p < 0.05). Pyrazinamide was used in addition to isoniazid and rifampicin in a significantly higher percentage of patients in the ATT-induced hepatitis group (70%) as compared with those in the control group (42%). No significant differences were observed between the two groups with regard to the rest of the parameters.
Introduction
Tuberculosis is becoming an increasingly important problem worldwide, especially with the alarming increase in the incidence of acquired immunodeficency syndrome (AIDS).' Drug-induced hepatotoxicity is a potentially serious adverse effect of the currently used antituberculosis chemotherapeutic regimens containing isoniazid, rifampicin and pyrazinamide. 
Results
There were 60 patients each in the study and control groups. The mean age of the patients in the ATT-induced hepatitis group was 40.7 ± 18 years and the majority of the cases (69%) were aged between 14-50 years. The mean ages of the patients in the study and control groups were not significantly different (table 1) . ATT-induced hepatitis was seen almost equally in males and females (table 1) .
The interval between the start of ATT and the appearance of hepatotoxicity varied from three to 135 days with a mean of 29.1 ± 27.6 days. In two-thirds of cases, hepatitis was evident within the first month of starting ATT while in nine cases (15%) the onset was delayed for more than two months after the start of treatment.
There was no significant difference between the two groups regarding the number of patients with a history of chronic alcoholism, chronic liver disease and hepatitis B virus carrier state. Determination of the acetylator status was possible in 32 patients in the study group and 54 patients in the control group. The percentages of rapid and slow acetylators were similar in the two groups (table 1) .
BMI was significantly lower in the ATTrelated hepatitis patients compared with those in the control group (table 1) . In patients with ATT-induced hepatitis, evidence of malnutrition (BMI < 18.5) was found in 32 patients (53.2%). Patients with malnutrition received significantly higher doses of isoniazid, rifampicin and pyrazinamide compared with patients without malnutrition (table 2).
All the patients in the study and control groups had received isoniazid and rifampicin. However, in addition, pyrazinamide was used in a significantly higher percentage of patients in the ATT-induced hepatitis group (70%) compared with patients in the control group (38.2%).
Discussion
There is wide disparity in the reported incidence of ATT-induced hepatitis in different studies, the incidence being much higher in studies from India (8-39%).316,17 than in those from Western countries (2-3%).18-2 Why only some patients who receive ATT develop hepatitis is not clear.
Whether some host factors, genetic predisposition, environmental factors, or some interaction among various factors is responsible is not known. The reported mortality from ATTinduced hepatitis after the development of jaundice varies from 4-12%. 21 22 No consensus In earlier studies it has been observed that the risk of ATT-induced hepatitis increases with advancing age, the highest incidence being in individuals older than 50 years.5 In the present study, no significant correlation of age with ATT-induced hepatitis was found. Although it has been reported that women are more prone to develop ATT-induced hepatitis,6 we did not find any female preponderance in our study patients. Such a lack of sex difference has been reported earlier." Contrary to observations in earlier studies,6'7 no significant difference was found in the prevalence of chronic alcoholism or chronic liver disease among patients in the study and control groups. This discrepancy is perhaps due to the small number of alcoholics in our study population (two) and also due to the fact that almost half of our patients were women, who do not traditionally consume alcohol in India. Another study has also reported that the presence of chronic liver disease does not confer any additional risk of ATT-induced hepatitis. '2 There is considerable controversy regarding the relationship of acetylator status to ATTinduced hepatotoxicity. Both rapid9'23 and slow acetylators324 have been reported to be more susceptible to drug-induced hepatitis. In our study the percentages of rapid and slow acetylators were similar in the ATT-related hepatitis patients and in the control group. Similar observations have been made by Gur- 
A recent study from Taiwan reported a higher incidence of ATT-induced fulminant and subacute hepatic failure in hepatitis B virus carriers compared to noncarriers.8 In our study no significant difference in the number of hepatitis B virus carriers was observed in the study and control groups; these results are in agreement with those of another study which found no increased risk in hepatitis B virus 26 carriers.
Low nutritional status is considered to be one of the factors contributing to the relatively high incidence of ATT-related hepatitis in studies from the developing countries.'0'27 Drug metabolism pathways including acetylation pathways have been shown to be deranged in states of protein energy malnutrition.28 In the present study, the BMI of patients with ATT-induced hepatitis was significantly lower than that of patients in the control group. Patients with malnutrition who developed drug-induced hepatitis also had a tendency to receive comparatively higher doses of antituberculosis drugs (table 2) .
In our study, pyrazinamide was used, in addition to isoniazid and rifampicin, in a significantly higher proportion of ATTinduced hepatitis patients compared to patients in the control group. This contradicts recent reports that pyrazinamide is not hepatotoxic when used at low doses.3 '9 In earlier reports of pyrazinamide hepatotoxicity, the drug was used in higher dosages.3' Patients with severe forms of tuberculosis are known to be at a higher risk of developing ATT-induced hepatitis.3'3' Since a large number of patients in our series had been started on ATT by physicians outside this hospital and reported to us only after the development of drug-induced hepatitis, we could not estimate reliably the pretreatment severity of their underlying tuberculosis. This may have confounded our observation regarding the use of pyrazinamide which we believe requires validation in a larger number of patients.
We conclude that lower nutritional status is the only factor studied that is definitely and rifampicin, appears to be associated with an increased incidence of hepatotoxicity associated with the development of ATTinduced hepatitis.
